Livoa LogoLivoa
Metastatic


Colorectal Cancer

(mCRC)

MSI Status
MMR protein deficient (dMMR) or Microsatellite Instability - High (MSI-H)
anti-PD-1/L1 Immunotherapy
Potentially


Resectable mCRC

Unresectable mCRC
Right Sided and


RAS/BRAF wt

Left Sided and


RAS/BRAF wt

RAS/BRAF mutation
Doublet
Doublet + bevacizumab
Triplet + bevacizumab
Doublet + anti-EGFR
Doublet + bevacizumab
Triplet + bevacizumab
Resectable?
Surgery + adjuvant FOLFOX OR CAPEOX
2nd OR 3rd line OR above
Yes
No
Right Sided and


RAS/BRAF wt

Left Sided and


RAS/BRAF wt

RAS/BRAF mutation
Doublet
Doublet + bevacizumab
Doublet + anti-EGFR
Triplet + bevacizumab
Resectable?
Surgery + adjuvant FOLFOX OR CAPEOX
2nd OR 3rd line OR above
Yes
No
For second line therapy and beyond consider:
BRAF V600E
Encorafenib + ant-EGFR
HER2 amplified, RAS/BRAF wt:
Trastuzumab +/- (pertuzumab OR lapatinib OR tucatinib)
Fam-trastuzumab deruxtecan
KRAS G12C
Adagrasib + cetuximab

ff

by uv

0
0 uses